A study to evaluate the safety and tolerability of JNJ-90106848 and to investigate how long JNJ-90106848 stays in and acts on the body (pharmacokinetics) and how the body responds to JNJ-90106848 (pharmacodynamics) when injected into healthy volunteer participants
Latest Information Update: 29 Sep 2025
At a glance
- Drugs JNJ 90106848 (Primary)
- Indications Inflammation
- Focus First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Janssen-Cilag
Most Recent Events
- 29 Sep 2025 New trial record